The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:046fb72db7fe07dc3c70c77bcff3b012]
San Raffaele Web site
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:046fb72db7fe07dc3c70c77bcff3b012]
San Raffaele Web site
Bio2RDF identifier
046fb72db7fe07dc3c70c77bcff3b012
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:046fb72db7fe07dc3c70c77bcff3b012
measure [clinicaltrials_vocabulary:measure]
The primary end point was free ...... ast enrolled patient complete.
description
San Raffaele Web site
identifier
clinicaltrials_resource:046fb72db7fe07dc3c70c77bcff3b012
title
The primary end point was free ...... ast enrolled patient complete.
@en
type
label
The primary end point was free ...... fb72db7fe07dc3c70c77bcff3b012]
@en